ClinicalTrials.gg
Not yet recruitingNCT06902428Updated Mar 30, 2025

Evaluating the Efficacy and Safety of of HSK44459 in Patients With Behçet's Disease

A Phase 2 interventional study of HSK44459 and Placebo in Behcet's Disease, sponsored by Haisco Pharmaceutical Group Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-03-30.

Sponsored by Haisco Pharmaceutical Group Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a phase 2, multi-center, randomised, double-blind, placebo-controlled study with an equal randomization among the HSK44459 dose 1, dose 2 and placebo treatment groups. The main objective is to evaluate of the efficacy and the secondary objective is to evaluate the safety and pharmacokinetic.

Read the detailed description

This study is a phase 2, multi-center, randomized, double - blind, placebo - controlled study designed to evaluate the efficacy and safety of HSK44459 in the treatment of patients with Behçet Disease (BD). Approximately 120 subjects will be randomized into this study.

The entire study will consist of 3 phases: a screening phase, a 12-week treatment phase, and a 4-week follow-up phase.

Screening: All subjects will undergo a screening period of up to 6 weeks before the first dose (Visit 3, Day 1).

Treatment phase: Eligible BD patients will be randomly assigned to the HSK44459 dose 1 group, the HSK44459 dose 2 group, or the placebo group. During the treatment period, HSK44459 or placebo will be administered twice daily for 12 weeks.

Follow-up phase: Subjects in the study (including those who withdraw from treatment for any reason) will have an additional 4 - week follow-up after the end of the last administration.

02

Conditions studied

  • Behcet's Disease
03

In context

Lead sponsor

Haisco Pharmaceutical Group Co., Ltd. is the lead sponsor of 118 studies on the registry; 51 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female subjects aged between 18 and 75 years (inclusive) at the time of signing the document.
  2. Diagnosed with Behçet's disease (BD) meeting the International Criteria for Behçet's Disease (ICBD, ICBD-2013) criteria.
  3. Suffered from at least 3 episodes of oral ulcers within 12 months prior to randomization.
  4. Had at least 2 oral ulcers present during the Screening Phase.
  5. Had received drug treatment for Behçet's disease.
  6. Eligible for systemic treatment of oral ulcers.
  7. Consented to participate in this trial, and voluntarily signed the informed consent form.

Exclusion criteria

Exclusion Criteria:

  1. Active involvement of major organs related to Behçet's disease - pulmonary (eg, pulmonary artery aneurysms), vascular (eg, thrombophlebitis), gastrointestinal (eg, gastrointestinal ulcers), and central nervous system (eg, meningoencephalitis) manifestations, and ocular lesions (eg, uveitis) requiring treatment.
  2. Subjects who have received the following immunomodulatory treatments, including:

    1. Hydroxychloroquine was used within 5 days prior to randomization;
    2. Colchicine was used within 7 days prior to randomization;
    3. Azathioprine, mycophenolate mofetil, baricitinib, or tofacitinib was used within 10 days prior to randomization;
    4. Cyclosporine, methotrexate, cyclophosphamide, thalidomide, or dapsone was used within 4 weeks (28 days) prior to randomization;
    5. Biological agents were used within 5 half-lives prior to randomization;
  3. Subjects who have received systemic treatment prior to randomization;
  4. Subjects who have used traditional Chinese patent medicines with immunomodulatory effects within 2 weeks prior to randomization; those who have taken traditional Chinese patent medicines that may affect the efficacy within 2 weeks prior to randomization;
  5. Patients who have previously received systemic treatment with phosphodiesterase 4 (PDE4) inhibitors;
  6. Patients who have used a strong inhibitor or inducer within 14 days prior to randomization or within 5 pharmacokinetic half-lives (whichever is longer); and patients who insist on taking a strong CYP3A4 inhibitor or inducer during the study period;
  7. Subjects who have used any medicinal product within 4 weeks prior to randomization or within 5 pharmacokinetic half-lives (whichever is longer);
  8. Laboratory tests during the screening period:

    • ≤ 90g/L;
    • White blood cell count \< 3.0×10⁹/L or white blood cell count > 14×10⁹/L;
    • \< 100×10⁹/L;
    • Estimated (eGFR) ≤ 45 ml/min/1.73 m²;
    • Total > 1.5×;
    • (AST) and alanine aminotransferase (ALT) are both > 1.5×ULN;
  9. Subjects with abnormalities in chest X-ray or CT examination at the time of screening, and as judged by the investigator, may place the subject at safety risk;
  10. Subjects with a history of active or recurrent bacterial, viral, fungal, mycobacterial, or other infections (including but not limited to tuberculosis and atypical mycobacteriosis, and C, and herpes zoster, but excluding onychomycosis) at the time of screening, or any episode of severe infection within 4 weeks prior to screening that required hospitalization or treatment with intravenous or oral antibiotics;
  11. Subjects with other diseases or immune-related chronic inflammatory diseases at the time of screening, such as rheumatic fever, rheumatoid arthritis, systemic lupus erythematosus, etc.;
  12. Subjects who have undergone or plan to undergo major surgery (evaluated as major surgery by the investigator) within 3 months prior to screening or during the study period;
  13. Subjects whose blood pressure was still not controlled after treatment with antihypertensive drugs within 3 months prior to screening, and whose blood pressure was ≥ 160/100 mmHg during the screening period;
  14. Subjects who had a thromboembolic event (including stroke and ) within 6 months prior to screening;
  15. Subjects who had any clinically significant heart disease (such as but not limited to unstable ischemic heart disease, class III/IV left ventricular failure, or myocardial infarction) discovered within 6 months prior to screening or those with clinically significant 12-lead abnormalities, and as judged by the investigator, may place the subject at safety risk or may interfere with the study evaluation;
  16. Subjects with a history of attempted suicide within 2 years prior to screening, or a history of major psychiatric illness requiring hospitalization within 3 years prior to screening;
  17. Subjects with a history of malignant tumor within 5 years prior to screening (except for patients with treated basal cell carcinoma of the skin, in situ squamous cell carcinoma of the skin, or in situ cervical cancer);
  18. History of gastrointestinal surgery or diseases (excluding appendectomy or simple hernia repair) that may interfere with the pharmacokinetics (PK) of the investigational drug;
  19. Subjects with active hepatitis B (positive for hepatitis B surface antigen (HBsAg) and hepatitis B virus DNA (HBV-DNA) higher than the upper limit of the normal range), positive for antibody, syphilis infection (positive for anti-TP test), or (HIV) infection (positive for anti-HIV) during the screening period;
  20. Subjects with a history of drug abuse, drug use, or excessive alcohol consumption within 3 months prior to screening. Excessive alcohol consumption means an average daily alcohol intake of > 2 units of alcohol;
  21. Subjects with a history of severe drug allergy or those allergic to the investigational medicinal product specified in the protocol;
  22. Pregnant and lactating women, or women who plan to become pregnant or breastfeed during the study period;
  23. Subjects whom the investigator deems to have any other factors that make them unsuitable for participating in this clinical study.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    In treatment period, subject will take placebo matching HSK44459 twice daily in the morning and in the evening for 12 weeks. The administration time of the drug should be relatively fixed every day.

    Drug: Placebo

  • Experimental
    HSK44459 dose 1

    In treatment period, subject will take higher dose of HSK44459 twice daily in the morning and in the evening for 12 weeks. The administration time of the drug should be relatively fixed every day.

    Drug: HSK44459

  • Experimental
    HSK44459 dose 2

    In treatment period, subject will take lower dose of HSK44459 twice daily in the morning and in the evening for 12 weeks. The administration time of the drug should be relatively fixed every day.

    Drug: HSK44459

Interventions

  • HSK44459, bid p.o.

  • DrugPlacebo

    Placebo, bid p.o.

06

What researchers measure

Primary outcomes

  1. Area Under the Curve for the Number of Oral Ulcers From Baseline Through treatment period.

    For the analysis of the primary endpoint, the count of oral ulcers included both existing and recurrent ulcers at each time point.

    Time frame: 12 weeks

Secondary outcomes

  1. Percentage of Participants Who Experienced an Oral Ulcer Complete Response at Week 12

    A complete response at week 12 was defined as participants being free of oral ulcers at that time point.

    Time frame: 12 weeks

  2. Baseline in Oral Ulcer Pain as Measured by Visual Analog Scale at Week 12

    The pain of oral ulcers was gauged via a 100-millimeter Visual Analog Scale. Participants were instructed to mark a single perpendicular line across the VAS at a position that corresponded to the intensity of their oral-ulcer pain experienced in the preceding 2 weeks. On this scale, 0 mm (the left-hand extremity) signified the absence of pain, while 100 mm (the right-hand extremity) represented the most excruciating pain one could envision. The measurement from the left-hand end of the scale to the perpendicular line was documented.

    Time frame: 12 weeks

  3. Percentage of Participants Who Experienced a Complete Response For Genital Ulcers at Week 12

    A complete response at week 12 was defined as participants being free of genital ulcers at that time point.

    Time frame: 12 weeks

  4. Change From Baseline in Genital Ulcer Pain as Measured by VAS Score at Week 12

    The pain of genital ulcers was gauged via a 100-millimeter Visual Analog Scale. Participants were instructed to mark a single perpendicular line across the VAS at a position that corresponded to the intensity of their genital-ulcer pain experienced in the preceding 2 weeks. On this scale, 0 mm (the left-hand extremity) signified the absence of pain, while 100 mm (the right-hand extremity) represented the most excruciating pain one could envision. The measurement from the left-hand end of the scale to the perpendicular line was documented.

    Time frame: 12 weeks

  5. Change From Baseline in Disease Activity as Measured by Behçet's Disease Current Activity Form (BDCAF) at Week 12

    The Behçet's Disease Current Activity Form (BDCAF) is composed of three component scores, namely the Behçet's Disease Current Activity Index (BDCAI) score, the Patient's Perception of Disease Activity, and the Clinician's Overall Perception of Disease Activity. The BDCAI encompasses 12 questions that focus on disease manifestations occurring within the past 4 weeks. These manifestations include the activity of oral and genital diseases, along with other symptoms of Behçet's Disease (BD) affecting the skin, joints, gastrointestinal (GI) tract, eyes, nervous system, and vascular system. The BDCAI score is calculated as the sum of the scores for these 12 items and can range from 0 to 12. A higher score on the BDCAI indicates a more severe level of disease activity (i.e., the condition is worsening).

    Time frame: 12 weeks

  6. Change From Baseline in Disease Activity as Measured by Behçet's Syndrome Activity Score (BSAS) at Week 12

    The Behçet's Syndrome Activity Score (BSAS) is composed of 10 questions that assess the number of new oral and genital ulcers and skin lesions, GI, CNS, vascular, and ocular involvement, and the participant's current level of discomfort. The Behçet's Syndrome Activity Score spans from 0 to 100. A higher score on this scale corresponds to a more severe level of disease activity. When there is a decrease in the score compared to the baseline value, it indicates an improvement in the patient's condition.

    Time frame: 12 weeks

  7. Change From Baseline in Behçet's Disease Quality of Life (BD Qol) Scores at Week 12

    The Behçet's Disease Quality of Life (BDQoL) questionnaire was designed to assess the impact of Behçet's disease on a participant's daily life. It includes 30 self-administered questions that evaluate the limitations imposed by the disease on the participant's activities and their emotional reactions to these limitations. The overall score is calculated by summing the responses to all 30 items, where each "yes" response is scored as 1 and each "no" response as 0. A total score of 0 indicates no effect of Behçet's disease on the participant's quality of life, while a score of 30 reflects the most significant impact. A decrease in the score from baseline signifies an improvement in the participant's quality of life.

    Time frame: 12 weeks

  8. Change From Baseline in Quality of Life as Measured by Short Form 36 Health Survey

    The SF-36 is a validated, self-administered 36-item general health status instrument often used in clinical trials and health services research. It consists of 8 scales: physical function (PF), role-physical (RP), vitality (VT), general health (GH), bodily pain (BP), social function (SF), role-emotional (RE), and mental health (MH).

    Time frame: 12 weeks

  9. Time to Oral Ulcer Complete Response

    The time to complete response of oral ulcers was defined as the interval from the date of the first dose to the date when a complete response was first attained during the treatment phase.

    Time frame: 12 weeks

  10. Percentage of Participants Exhibiting No Oral Ulcers After a Complete Response

    The definition encompasses participants who, subsequent to achieving a complete response (characterized by the absence of oral ulcers) prior to week 12, maintained an oral ulcer-free status throughout the entirety of the period up to and including week 12.

    Time frame: 12 weeks

  11. Percentage of Participants Who Achieved an Oral Ulcer Complete Response at Week 6 and Remained Oral Ulcer-Free for at Least 6 Additional Weeks

    Participants who were oral ulcer-free at week 6 and maintained an oral ulcer-free status throughout the entirety of the period up to and including week 12.

    Time frame: 12 weeks

  12. Number of recurrences of oral ulcers after complete response through week 12

    The number of oral ulcers reported upon the initial loss of complete response. This refers to the first occurrence where, subsequent to achieving complete response, a participant experiences a recurrence of oral ulcers during the treatment phase.

    Time frame: 12 weeks

  13. The incidence rate and severity of adverse events

    An Adverse Event (AE) refers to all adverse medical events that occur to subjects in a clinical study. It can manifest as symptoms/signs, diseases, or abnormal laboratory test results, but it is not necessarily causally related to the investigational medicinal product. In this study, all adverse events that occur from the time of signing the informed consent form until the end of the safety follow-up period will be recorded.

    Time frame: 16 weeks

  14. Maximum Plasma Concentration (Cmax)

    the population pharmacokinetic (popPK) characteristics Cmax of HSK44459 in subjects

    Time frame: 12 weeks

  15. Elimination half-life (T1/2)

    the population pharmacokinetic (popPK) characteristics T1/2 of HSK44459 in subjects

    Time frame: 12 weeks

  16. Area under drug time curve (AUC)

    the population pharmacokinetic (popPK) characteristics AUC of HSK44459 in subjects

    Time frame: 12 weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2025; primary completion for Jun 2026, 14 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2025
First posted
Mar 30, 2025
StartEst.
Mar 24, 2025
Primary completionEst.
Jun 5, 2026
CompletionEst.
Jul 3, 2026
Last update
Mar 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06902428
Responsible party
Sponsor
First posted
Mar 30, 2025
Start date
Mar 24, 2025 (estimated)
Primary completion
Jun 5, 2026 (estimated)
Completion
Jul 3, 2026 (estimated)
Last update
Mar 30, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HSK44459

Start the discussion